Literature DB >> 20037838

Model for end-stage liver disease versus the Child-Pugh score in predicting the post-transplant 3-month and 1-year mortality in a cohort of Chinese recipients.

Zhiyong Guo1, Xiaoshun He, Linwei Wu, Weiqiang Ju, Anbin Hu, Qiang Tai, Dongping Wang, Yi Ma, Guodong Wang, Xiaofeng Zhu, Jiefu Huang.   

Abstract

PURPOSE: This study evaluated the performance of the model for end-stage liver disease (MELD) in predicting post-transplant survival in a cohort of Chinese patients, and compared its predictive ability with that of the Child-Pugh score.
METHODS: The study enrolled 117 adult Chinese patients undergoing liver transplantation for benign end-stage liver diseases from January 1998 to January 2007 to evaluate the baseline characteristics and outcomes.
RESULTS: In a median follow-up duration of 90 weeks (range 0.2-373 weeks), 30 patients died. The 3-month and 1-year mortality rates of recipients in group 1 (MELD score <28) were 1.1% and 5.6%, in group 2 (MELD score 28-38) 18.8% and 50.0%, and in group 3 (MELD score >38) 91.7% and 91.7%, respectively. A statistical difference was observed in the mortality rates between the three groups (P < 0.001). At 3 months, the area under the receiver operating characteristic curve of the MELD (0.950) was significantly higher than that of the Child-Pugh score (0.810; P < 0.05).
CONCLUSIONS: Both the MELD and Child-Pugh score are valid models to predict the short-term or medium-term outcome of Chinese recipients undergoing liver transplantation for benign end-stage liver diseases. The MELD is superior to the Child-Pugh score in predicting the 3-month mortality post-transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 20037838     DOI: 10.1007/s00595-009-4114-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  27 in total

1.  Primary nonfunction (PNF) in the MELD Era: An SRTR database analysis.

Authors:  S R Johnson; S Alexopoulos; M Curry; D W Hanto
Journal:  Am J Transplant       Date:  2007-02-07       Impact factor: 8.086

2.  MELD--an imperfect, but thus far the best, solution to the problem of organ allocation.

Authors:  John R Lake
Journal:  J Gastrointestin Liver Dis       Date:  2008-03       Impact factor: 2.008

3.  Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications.

Authors:  Teh-Ia Huo; Han-Chieh Lin; Jaw-Ching Wu; Ming-Chih Hou; Fa-Yauh Lee; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Clin Transplant       Date:  2006 Mar-Apr       Impact factor: 2.863

4.  Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.

Authors:  Satheesh Nair; Sumita Verma; Paul J Thuluvath
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

Review 5.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

Review 6.  Improving liver allocation: MELD and PELD.

Authors:  Richard B Freeman; Russell H Wiesner; John P Roberts; Suzanne McDiarmid; Dawn M Dykstra; Robert M Merion
Journal:  Am J Transplant       Date:  2004       Impact factor: 8.086

7.  A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation.

Authors:  Nicholas N Onaca; Marlon F Levy; Edmund Q Sanchez; Srinath Chinnakotla; Carlos G Fasola; Mark J Thomas; Jeffrey S Weinstein; Natalie G Murray; Robert M Goldstein; Goran B Klintmalm
Journal:  Liver Transpl       Date:  2003-02       Impact factor: 5.799

8.  MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients.

Authors:  Walter K Kremers; Marrije van IJperen; W Ray Kim; Richard B Freeman; Ann M Harper; Patrick S Kamath; Russell H Wiesner
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

9.  Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.

Authors:  Adnan Said; John Williams; Jeremy Holden; Patrick Remington; Ronald Gangnon; Alexandru Musat; Michael R Lucey
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

10.  Antiviral therapy for hepatitis C in the setting of liver transplantation.

Authors:  Gregory T Everson; Clark C Kulig
Journal:  Curr Treat Options Gastroenterol       Date:  2006
View more
  4 in total

1.  Predicting Mortality Across a Broad Spectrum of Liver Disease-An Assessment of Model for End-Stage Liver Disease (MELD), Child-Turcotte-Pugh (CTP), and Creatinine-Modified CTP Scores.

Authors:  Yogesh K Chawla; Ramesh Chillal Kashinath; Ajay Duseja; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-01-02

2.  The MELD score predicts the short-term and overall survival after liver transplantation in patients with primary sclerosing cholangitis or autoimmune liver diseases.

Authors:  Katrin Hoffmann; Ulf Hinz; Norbert Hillebrand; Tom Ganten; Daniel Gotthardt; Thomas Longerich; Peter Schirmacher; Peter Schemmer
Journal:  Langenbecks Arch Surg       Date:  2014-08-09       Impact factor: 3.445

3.  The predictive value of MELDNa (model for end-stage liver disease-sodium) and mean platelet volume/platelet count for patients' 30-day mortality after liver transplantation.

Authors:  Vecihe Bayrak; Mehmet Çağatay Gürkök; Ferhan Demirer Aydemir; Bişar Ergün; Tufan Egeli; Nurcan Şentürk Durukan; Tarkan Ünek; Necati Gökmen
Journal:  Clin Exp Hepatol       Date:  2022-03-31

Review 4.  Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature.

Authors:  Kristin B Klein; Taenia D Stafinski; Devidas Menon
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.